Noninvasive Biomarker for Predicting Treatment Response to Concurrent Chemoradiotherapy in Patients with Hepatocellular Carcinoma
10.13104/imri.2019.23.4.351
- Author:
Yong Eun CHUNG
1
;
Jun Yong PARK
;
Jin Young CHOI
;
Myeong Jin KIM
;
Mi suk PARK
;
Jinsil SEONG
Author Information
1. Department of Radiology, Yonsei University College of Medicine, Seoul, Korea. radpms@yuhs.ac
- Publication Type:Original Article
- Keywords:
Hepatocellular carcinoma;
Ultrasonography;
Perfusion imaging;
Magnetic resonance imaging, Chemoradiotherapy, Biomarkers
- MeSH:
Biomarkers;
Carcinoma, Hepatocellular;
Chemoradiotherapy;
Humans;
Magnetic Resonance Imaging;
Methods;
Perfusion Imaging;
Response Evaluation Criteria in Solid Tumors;
ROC Curve;
Sensitivity and Specificity;
Ultrasonography
- From:Investigative Magnetic Resonance Imaging
2019;23(4):351-360
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To investigate noninvasive biomarkers for predicting treatment response in patients with locally advanced HCC who underwent concurrent chemoradiotherapy (CCRTx).MATERIALS AND METHODS: Thirty patients (55.5 ± 10.2 years old, M:F = 24:6) who underwent CCRTx due to advanced HCC were enrolled. Contrast-enhanced US (CEUS) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) were obtained before and immediately after CCRTx. The third CEUS was obtained at one month after CCRTx was completed. Response was assessed at three months after CCRTx based on RECIST 1.1. Quantitative imaging biomarkers measured with CEUS and MRI were compared between groups. A cutoff value was calculated with ROC analysis. Overall survival (OS) was compared by the Breslow method.RESULTS: Twenty-five patients were categorized into the non-progression group and five patients were categorized into the progression group. Peak enhancement of the first CEUS before CCRTx (PE1) was significantly lower in the non-progression group (median, 18.6%; IQR, 20.9%) than that in the progression group (median, 59.1%; IQR, 13.5%; P = 0.002). There was no significant difference in other quantitative biomarkers between the two groups. On ROC analysis, with a cutoff value of 42.6% in PE1, the non-progression group was diagnosed with a sensitivity of 90.9% and a specificity of 100%. OS was also significantly longer in patients with PE1 < 42.6% (P = 0.014).CONCLUSION: Early treatment response and OS could be predicted by PE on CEUS before CCRTx in patients with HCC.
